Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/105923
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Biomedical Engineering | - |
dc.creator | Xu, P | en_US |
dc.creator | Zhang, Y | en_US |
dc.creator | Chang, T | en_US |
dc.creator | Jiang, L | en_US |
dc.creator | Lv, Z | en_US |
dc.creator | Zhang, Y | en_US |
dc.creator | Xu, H | en_US |
dc.creator | Zhang, D | en_US |
dc.creator | Lan, T | en_US |
dc.creator | Cui, Y | en_US |
dc.creator | Hua, Z | en_US |
dc.creator | Gao, C | en_US |
dc.creator | Lu, J | en_US |
dc.creator | Huang, Q | en_US |
dc.creator | Tian, J | en_US |
dc.creator | Ma, J | en_US |
dc.creator | Wang, J | en_US |
dc.date.accessioned | 2024-04-23T04:32:21Z | - |
dc.date.available | 2024-04-23T04:32:21Z | - |
dc.identifier.issn | 0025-7974 | en_US |
dc.identifier.uri | http://hdl.handle.net/10397/105923 | - |
dc.language.iso | en | en_US |
dc.publisher | Wolters Kluwer Health | en_US |
dc.rights | Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | en_US |
dc.rights | The following publication Xu, Peng MDa; Zhang, Ying MDa; Chang, Tianying MMb; Jiang, Li MDc; Lv, Zhiguo MDa; Zhang, Yibin MDc; Xu, Hanying MDc; Zhang, Dongmei MMd; Lan, Tianye MDa; Cui, Yingzi MDb; Hua, Zhen MDe; Gao, Chengfei MDf,g; Lu, Jing MDh; Huang, Qingxia MDh; Tian, Jinhui MDi; Ma, Jihui MDj; Wang, Jian MDa,*. Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis. Medicine 101(50):p e31454, December 16, 2022 is available at https://doi.org/10.1097/MD.0000000000031454. | en_US |
dc.subject | Bayesian network meta-analysis | en_US |
dc.subject | Immunosuppressive drugs | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Myasthenia gravis | en_US |
dc.subject | Protocol | en_US |
dc.subject | Systematic review | en_US |
dc.title | Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis : a protocol for systematic review and network meta-analysis | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 101 | en_US |
dc.identifier.issue | 50 | en_US |
dc.identifier.doi | 10.1097/MD.0000000000031454 | en_US |
dcterms.abstract | Background: Immunosuppressive drugs are routinely used to treat myasthenia gravis (MG). However, current recommendations provide limited evidence to support treatment options, leading to considerable variation in practice among healthcare specialists. Hence, we present a protocol for a systematic review and network meta-analysis (NMA) to update the evidence by comparing the efficacy and acceptability of oral immunosuppressive drugs for the treatment of MG. | - |
dcterms.abstract | Methods: We will conduct a systematic review and NMA of all randomized controlled trials evaluating the following oral immunosuppressive drugs for the treatment of MG. Published studies will be searched using the following databases from inception to November 23, 2021: CENTRAL, the CINAHL, MEDLINE, Embase, PsycINFO, Web of Science, and 3 Chinese databases (Chinese Biomedical Literatures Database, CNKI, and Wan Fang database). Assessment of study eligibility and data extraction will be conducted independently by 2 reviewers. The main outcome will be a quantitative MG scoring system. We will conduct Bayesian NMA to synthesize all evidence for each outcome and obtain a comprehensive ranking of all treatments. The quality of the evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations framework. | - |
dcterms.abstract | Results: The objective of this study was to assess the relative clinical efficacy and acceptability of first-line immunosuppressants for the treatment of MG, using a systematic review and NMA approach. | - |
dcterms.abstract | Conclusion: In the absence of head-to-head trials comparing therapies, evidence from this NMA of available clinical trials will inform clinicians, patients, and families the risk-benefit profiles of different treatment options. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Medicine, 16 Dec. 2022, v. 101, no. 50, e31454 | en_US |
dcterms.isPartOf | Medicine | en_US |
dcterms.issued | 2022-12-16 | - |
dc.identifier.scopus | 2-s2.0-85144557696 | - |
dc.identifier.pmid | 36550882 | - |
dc.identifier.eissn | 1536-5964 | en_US |
dc.identifier.artn | e31454 | en_US |
dc.description.validate | 202404 bcch | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | - |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | National Key Research and Development Program; National Administration of Traditional Chinese Medicine; Project of Science and Technology Department of Jilin Province; Administration of Traditional Chinese Medicine of Jilin Province | en_US |
dc.description.pubStatus | Published | en_US |
dc.description.oaCategory | CC | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
comparative_the_efficacy_and_acceptability_of.90.pdf | 776.69 kB | Adobe PDF | View/Open |
Page views
18
Citations as of Jun 30, 2024
Downloads
4
Citations as of Jun 30, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.